340B Drug Pricing Program
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B program and its growth and impacts on patients.
AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and communities they serve.
The U.S. Senate Committee on Health, Education, Labor and Pensions Oct. 23 will hold a hearing titled, “The 340B Program: Examining Its Growth and Impact on Patients.”
Senate HELP Committee to hold hearing on 340B program
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted…
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
In 2022, tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total benefits to their communities, according to a new AHA report.
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last…
AHA, others file amicus brief against Novartis motion to block Rhode Island 340B Contract Pharmacy Law -9-16-2025.
AHA, others file amicus brief against AbbVie’s motion to block Rhode Island’s 340B Contract Pharmacy Law-9-18-2025.